Xvivo Perfusion AB (publ) (STO:XVIVO)

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Thoracic	509.32M	555.24M	384.36M	296.35M	198.63M
Thoracic Growth	-8.27%	44.46%	29.70%	49.20%	-
Services	77.53M	87.76M	79.14M	48.08M	6.05M
Services Growth	-11.66%	10.89%	64.61%	694.68%	-
Abdominal	225.32M	179.42M	134.04M	70.86M	53.71M
Abdominal Growth	25.58%	33.86%	89.16%	31.94%	-
Total	812.17M	822.42M	597.54M	415.29M	258.39M
Total Growth	-1.25%	37.63%	43.88%	60.73%	43.66%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
USA	427.88M	471.54M	308.10M	224.87M	119.64M
USA Growth	-9.26%	53.05%	37.01%	87.96%	31.98%
North and South America, Excluding The US	22.26M	36.29M	25.62M	25.49M	19.03M
North and South America, Excluding The US Growth	-38.66%	41.63%	0.53%	33.94%	8.85%
Asia/Pacific and Oceania	49.20M	43.33M	42.18M	18.81M	13.38M
Asia/Pacific and Oceania Growth	13.55%	2.74%	124.24%	40.54%	-
Sweden	6.69M	3.99M	4.22M	1.67M	2.29M
Sweden Growth	67.68%	-5.38%	152.57%	-27.17%	75.57%
EMEA Excluding Sweden	306.13M	267.27M	-	-	-
EMEA Excluding Sweden Growth	14.54%	-	-	-	-
The Netherlands	-	-	30.22M	25.99M	19.42M
The Netherlands Growth	-	-	16.29%	33.83%	-
Italy	-	-	58.93M	21.48M	14.78M
Italy Growth	-	-	174.32%	45.32%	-
EMEA Excluding Sweden,Netherlands and Italy	-	-	128.28M	96.99M	69.84M
EMEA Excluding Sweden,Netherlands and Italy Growth	-	-	32.27%	38.86%	-
Total	812.17M	822.42M	597.54M	415.29M	258.39M
Total Growth	-1.25%	37.63%	43.89%	60.72%	43.66%

Source: S&P Global Market Intelligence.